

Synthesis, Bio-electrochemical and Pharmacological Study of Co-Atropine complexes

Dr. Rakesh Choure^{1*} and Dr. Ganpat Singh Argal²

¹Assistant Professor, Department of Chemistry, PMCoE Government JST PG College Balaghat MP

²Assistant Professor, Department of Chemistry, Government SMS Model science College Gwalior MP

Abstract:-

The Co-Atropine complex may have potential applications in medicinal chemistry, as atropine is used in the treatment of certain medical conditions such as bradycardia and as a pre-anesthetic to decrease salivation. Additionally, the complexation of atropine with cobalt could potentially enhance its therapeutic effects or alter its pharmacokinetic properties. In the present study, the drug has been modified by complex formation with absolute methanol and concentrated sulphuric acid following standard procedures to increase its potency. IR spectra of Co- atropine complex has taken. The analytical data indicates that a complex form of the drug, Co-Atropine, is formed in a 1:1 ratio. To study the interaction between drugs and metal complexes, differential pulse polarography (DPP) has been used. These techniques are simple and cost-effective, making them suitable for qualitative and quantitative determination of active drug compounds. In a pharmacological study, modified atropine showed more potency compared to its parent drug.

Date of Submission: 12-09-2026

Date of Acceptance: 25-09-2026

I. Introduction:-

In the modern age, an analytical chemist, solves his problems of chemical analysis, quantitative of qualitative, by making use of some instrumentation techniques like polarography, pH metry, spectroscopy etc. Past three decades have witnessed a wider use of electroanalytical techniques for the study of metal complexes in solution. For metal ligand system it is possible to determine the degree of formation, distribution and stability constants of all species present.

Polarography, finds an extensive use in the determination of various organic and inorganic depolarizers present even in micro to ultra micro quantity. For a current voltage curve, if the specific rate of the electrochemical reaction is very high, so that the current is controlled essentially by diffusion process, the calculation of the shape of the current-voltage curves is relatively very easy and such process is termed as the reversible electrode process. In the last two-three decades, the technique has found increasing application as a means of identifying the stoichiometry and formation constants of coordination compounds. Looking at the usefulness of polarographic methods in the analysis of organic compounds, it has been used to study the chemistry of atropine (in the study of adsorption, complex formation, inhibition of chain oxidations, and the mechanism of organic reactions).

II. Experimental

All the chemical used were of Himedia/BDH/CDH grade. The sulphates of Co²⁺ were used. Double distilled water was used to prepare all the solutions. Stock solution of 1M Borate buffer and .01M Atropine was prepared in double distilled water and alcohol.

Experimental sets were prepared by keeping overall metal ion and supporting electrolyte (borate buffer) concentrations fixed at 1.0mM and 1.0M respectively. The pH of the solution was adjusted to 8.2 ±0.1. Necessary amount of boric acid and sodium Hydroxide solution was used to adjust the pH of test solutions. Experimental set was prepared by taking 1ml of sample solution and 10ml of borate buffer as supporting electrolyte in a polarographic cell and the total volume was made is 50ml with distilled water. The pH of the test solution was adjusted to 8.2±0.1.

III. Results and Discussion

Atropine and its complexes gave well-defined cathodic reduction wave at pH = 8.2±0.1 in 1M Borate buffer. The plots of i_d vs $\sqrt{h_{corr}}$ yielded straight lines in each case, passing through the origin confirming the diffusion controlled nature of the reduction process.

Effect of ligand concentration:-

On increasing the ligand concentration in each set and subjecting these experimental sets to polarography. It was observed that the half wave potential shifted to more electronegative value. The plot of change in half wave potential with logarithm of change in ligand concentration yielded a straight line, suggesting the formation of single complex species in case of Co(II)-Atropine system, Lingane's treatment of the observed polarographic data in case of Co(II)-Atropine system, revealed the stoichiometry and formation constants of the complexes formed. The results have been tabulated. (Table- 3-1.3 and Table- 3-1.4)

Table- 1.1 Formation Constants of Atropine complexe

Complex	Stoichiometry	Formation Constant $\log \beta_1$
Co-(II)-Atropine	1:1	5.85

Table- 1.2-Polarographic data on Co(II) – Atropine complex system.

Co(II)=1.0 mM, 1.0 M Borate buffer pH = 8.2±0.1,

Concentration of ligand	$\log C_x$	$E_{1/2}$
0.0000	-	-1.40
0.0005	-3.301	-1.41
0.0010	-3.000	-1.418
0.0020	-2.698	-1.431
0.0030	-2.522	-1.438
0.0040	-2.397	-1.443

$\log \beta_1 = 5.85$

Polarograms of Co(II)-Atropine complex




Fig 1.1 (a) Direct current Polarogram of Co(II)-atropine complex in borate buffer (0.2M) at pH 8.2±0.1.




Fig 1.2 (b) Differential pulse Polarogram of Co(II)- atropine complex in borate buffer (0.2M) at pH 8.2±0.1.




Fig. 1.3 Co(II)-Atropine Complex

IR spectral analysis of Co(II)-Atropine Complex

On comparing the IR spectra of atropine and its Fe(II) complex, it was observe that the band at 1730 cm^{-1} due to C=O group in the spectrum of pure drug disappeared in the spectrum of its Co(II) complex and also the sharp -OH signal at 3608 cm^{-1} observed in atropine is shifted to 3650 cm^{-1} in the spectrum of Fe(II)-atropine complex, which confirms involvement of C=O and -OH in the complexation of the drug with Fe(II). Thus on the basis of polarographic and IR studies a tentative structure to 1:1, Co(II)-atropine complex may be as under:




Fig.1.4- IR Spectra of Co-Atropine complex

Pharmacological Experiments

A rabbit was placed in a Rabbit holder (box) keeping the head out side. The size of the rabbit pupil of both eyes was observed. The effect of light reflex of the rabbit's eye to and fro was observed. The corneal reflex was examined by touching a side of the cornea with a cotton piece. A few drops of atropine were instilled in the conjunctiva (4-6 times) over a period of 8-10 minutes in the right eye of the rabbit. The left eye of the rabbit served as control. The pupillary size was recorded after 10 minutes of drug instillation and the data was tabulated. The experiment was repeated with atropine complexes. The table shows that Co(II)-Atropine complex is more potency anesthetic drug of the complex under study.

Table-1.1:- Effect of Atropine and its complexes Co(II) instillation on the pupillary size of experimental rabbit

S. No.	Time interval in (minutes)	Control	Standard drug Atropine	Complex with Co
1.	Initial	.7cm	.7cm	.7cm
2.	After 10 minutes	.7cm	.8cm	.8cm
3.	20 minutes	.7cm	.9cm	.9cm
4.	30 minutes	.7cm	1.3cm	1.4cm
5.	40 minutes	.7cm	1.0cm	1.6cm
6.	50 minutes	.7cm	.9cm	1.0cm
7.	60 minutes	.7cm	.8cm	.9cm
8.	70 minutes	.7cm	.7cm	.8cm
9.	80 minutes	.7cm	.7cm	.7cm
10.	90 minutes	.7cm	.7cm	.7cm

IV. Conclusion

The observed analytical data clearly speaks the formation of modified form of the drug in 1:1 ratio in each case.

Results of pharmacological study on the anesthetic activities of above systems showed that the modified drug is found to be more potent than parent atropine drug.

On the basis of reported data and ongoing discussion it could be concluded that the proposed electroanalytical methods provide accurate and precise data on trace analysis of atropine and its modified forms. The techniques are best suited because of simplicity as well as economics of the procedure for the simultaneous qualitative and quantitative determination of traces of active principles of drugs and may be recommended for their possible use in medicinal industries. The author also recommends the modified drugs to the therapeutic experts to ascertain the possible use of the modified forms as more potent anesthetics in lieu of parent atropine drug.

References

- [1]. Weinberg, G. L., VadeBoncouer, T., Ramaraju, G. A., Garcia-Amaro, M. F., Cwik, M. J., "Pretreatment or resuscitation with a lipid infusion shifts the dose-response to bupivacaine-induced asystole in rats", *Anesthesiology*, **88**: 1071-5, 1998.
- [2]. Weinberg, G., Ripper, R., Feinstein, D. L., Hoffman, W., "Lipid emulsion infusion rescues dogs from bupivacaine-induced cardiac toxicity", *Regional Anesthesia and Pain Medicine*, **28**: 198-202, 2003.
- [3]. Picard, J., Meek, T., "Lipid emulsion to treat overdose of local anaesthetic: the gift of the glob", *Anesthesia*, **61**:107-9, 2006.
- [4]. Rosenblatt, M. A., Abel, M., Fischer, G. W., Itzkovich, C. J., Eisenkraft, J. B., "Successful Use of a 20% lipid emulsion to resuscitate a patient after a presumed bupivacaine-related cardiac arrest", *Anesthesiology*, **105**:217-8, 2006.
- [5]. Litz, R. J., Popp, M., Stehr, S. N., Koch, T., "Successful resuscitation of a patient with ropivacaine-induced asystole after axillary plexus block using lipid infusion", *Anaesthesia*, **61**:800-1, 2006.
- [6]. Rang, H. P., Dale, M. M., Ritter, J. M., Flower, R. J., "Rang and Dale's Pharmacology", Elsevier Churchill Livingstone, **153**, 2007.
- [7]. Robert, S., Holzman, M. D., "The Legacy of Atropos". *Anesthesiology*, **89** (1): 241-249, 1998-07.
- [8]. Arthurs, A. J., Davies, R., "Atropine - a safe drug", *Anesthesia*, **35**: 1077-1079, 1980.
- [9]. Gilman, A. G., Goodman, L. S., Rall, T. W., Murad, F. and Weiner, N., "Atropine, scopolamine, and related antimuscarinic drugs. In: The Pharmacological Basis of Therapeutics", 7th ed. MacMillan, New York, **130-138**, 1985.
- [10]. Lullmann, H., Schmaus, H., Staemmler, E., Ziegler, A., "Comparison of atropine and dextetidine in treatment of intoxications by selected organophosphates *Acta Pharmacol et Toxicol*", **50**: 230-237, 1982.
- [11]. McEvoy, G., "Anticholinergic agents", AHFS drug information, American Hospital Formulary Service, Bethesda, MD 1222-1228, 2002.
- [12]. Berghem, L., Bergman, U., Schildt, B., "Plasma atropine concentrations determined by radioimmunoassay after single-dose iv and im administration", *Br J Anaesth*, **52**: 597-601, 1980.
- [13]. Finar, I.L., "Organic Chemistry, Vol. 2 4th. Edn", Longman, 631-639, 1965,
- [14]. Willstätter, R., "Ber", **34**, pp. 129 and 3163, 1901.

- [15]. Drazen and Austen, "Atropine modification of the pulmonary effects of chemical mediators in the guinea.", J. Appl Physiol., **38**: 834-838, 1975.
- [16]. Wecker, Lynn., Dettbarn, Wolf-D., Schmidt, Dennis E., "Choline Administration: Modification of the Central Actions of Atropine", Science, **199**(4324), 86-87, 2000.
- [17]. Monteiro, R., Daniela, Campagnol, Leticia, Parrilha, R., and Luisa, Furlan, Z., "Evaluation of cardiorespiratory effects of combinations of dexmedetomidine and atropine in cats", Journal of Feline Medicine & Surgery, Volume 11, Pages **783-792**, October 2009.
- [18]. Brock-utne, J. G., Rubin, J., Downing, J. W., Dimopoulos, G. E., M., Moshal, G., Naicker, M., "The administration of metoclopramide with atropine A drug interaction effect on the gast-oesophageal sphincter in man", Anaesthesia, **31**(9), 1186-1190, 1976.
- [19]. Stephan, Cherkez, Haim, Yellin, Yoel, Kashman., Bella, Yaavetz, Mordechai, Sokolovsky., "Structure-activity relationship in a new series of atropine analogs. I. N,N'-Disubstituted 6,7-diazabicyclo[3.2.2]nonane derivatives", J. Med. Chem., **22** (1), 18-21, 1979,
- [20]. Portillo, R., Sanz-Pedrero, P., Bashuelves, F., "Polarographic determination of alkaloids. I. Polarographic behavior of atropine", **21**(1):37-42, 1955.
- [21]. Volke, J., Volkeova, V., "Polarographic behavior of alkaloids", **3**(8):289-92, 1954.
- [22]. Kiriakov, Kh., Petkov, P., "a possibility of polarographic determination of alkaloids used as complex salt K(BIJ4)", **15**:297-300,1964.
- [23]. Pandian, Bothi, Raja., and Mathur, Gopalakrishnan, Sethuraman., "Atropine sulphate as corrosion inhibitor for mild steel in sulphuric acid medium Materials", Letters, **62**(10-11), 1602-1604, 2008.
- [24]. Latifa, Rabi., Adnane, Moutaouakkil., Mohamed, Blaghen., "Ionophoric properties of atropine: complexation and transport of Na⁺, K⁺, Mg²⁺ and Ca²⁺ ions across a liquid membrane", Natural Product Research: Formerly Natural Product Letters, 1478-6427, **22**(6), 547-553, 2008.
- [25]. Terufumi, F., ujiwara, Imdad, U., Mohammadzai, Katsumi, Murayama and Takahiro, Kumamaru., "Solvent Extraction Coupled On-Line to a Reversed Micellar Mediated Chemiluminescence Detection System for Trace-Level Determination of Atropine" Anal. Chem., **72**(7), 1715-1719, 2000.
- [26]. Ryang, S., Takei, S., Kawai, T., Imaizumi, Y., Watanabe, M., "Atropine-resistant relaxation induced by high K⁺ in iris dilator muscle of the rat and pig", 86-87, 2000.
- [27]. Seo, K, Y., Kim, C, Y., Lee, J, H., Lee, J, B., Kim, E, K., "Amniotic membrane transplantation for necrotising conjunctival ulceration following subconjunctival atropine injection", Br J Ophthalmol; 86: 1316-1317, 2002.
- [28]. William, Mushin, W., Galloon, S., and Lewis-Faning, E., "Anti-Sialogogue and Other Effects of Atropine Mucate" The British Medical Journal, **2**, 652-655, 1953.
- [29]. Grace, Gray, W. and Maurice, Seevers, H., "in vivo observations on the nature of atropine achyphylaxis exhibited by intestinal smooth muscle", J. Pharmacol., **113**: 319-331, 1955.
- [30]. Kaila, T., Korte, J.M., Saari, K. M., "Systemic bioavailability of ocularly applied 1% atropine eye drops", Acta Ophthalmol Scand, **77**:193-196, 1999.
- [31]. Lahdes, K., Kaila, T., Huupponen, R., Salminen, L., Lisalo, E., "Systemic absorption of topically applied ocular atropine", Clin Pharmacol Ther, **44**, 310-314,1988.
- [32]. Merlie, G. J., Weitz, H., Martin, J. H., McClay, E. F., Adler, A. G., Fellin, F. M., Libonati, M., "Cardiac dysrhythmias associated with ophthalmic atropine", Arch Intern Med., **146** : 45-47, 1986.
- [33]. Roger, Kenneth, Eagan., M. D. and Pninit, Varol, M. D., "Atropine Ophthalmic Administration Unmasking Undiagnosed Diabetic Gastroparesis", **22**(3): 139-140, 2004.
- [34]. Guo, Zhang, H., James, Melvin, E., "Altered Responses to Agonists after Chronic In Vivo Atropine Administration in Rat Parotid Acini", Rochester Caries Research Center, **4**(3): 427-434 1993.
- [35]. Virtanen, R., Kanto, J., Iisalo, E., Iisalo, EU., Salo, M., Sjövall, S., "Pharmacokinetic studies on atropine with special reference to age", **26**(4): 297-300, 1982.